← Back to Screener
AbCellera Biologics Inc. Common Shares (ABCL)
Price$3.91
Favorite Metrics
Price vs S&P 500 (26W)-36.23%
Price vs S&P 500 (4W)8.45%
Market Capitalization$1.22B
All Metrics
Book Value / Share (Quarterly)$3.22
P/TBV (Annual)1.10x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-46.31%
Cash Flow / Share (Quarterly)$-0.58
Price vs S&P 500 (YTD)13.11%
Net Profit Margin (TTM)-194.89%
EPS (TTM)$-0.49
10-Day Avg Trading Volume3.09M
EPS Excl Extra (TTM)$-0.49
Revenue Growth (5Y)-20.27%
EPS (Annual)$-0.49
ROI (Annual)-15.14%
Net Profit Margin (5Y Avg)-214.23%
Cash / Share (Quarterly)$1.78
Revenue Growth QoQ (YoY)788.18%
ROA (Last FY)-10.79%
Revenue Growth TTM (YoY)160.55%
EBITD / Share (TTM)$-0.62
ROE (5Y Avg)-3.09%
Operating Margin (TTM)-288.98%
Cash Flow / Share (Annual)$-0.58
P/B Ratio1.26x
P/B Ratio (Quarterly)1.06x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)14.47x
Net Interest Coverage (TTM)79.25x
ROA (TTM)-10.73%
EV / EBITDA (TTM)4.28x
EPS Incl Extra (Annual)$-0.49
Current Ratio (Annual)11.32x
Quick Ratio (Quarterly)11.08x
3-Month Avg Trading Volume3.70M
52-Week Price Return67.78%
EV / Free Cash Flow (Annual)3.61x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.09
P/S Ratio (Annual)16.18x
Asset Turnover (Annual)0.06x
52-Week High$6.51
Operating Margin (5Y Avg)-381.08%
EPS Excl Extra (Annual)$-0.49
CapEx CAGR (5Y)23.81%
Tangible BV CAGR (5Y)5.36%
26-Week Price Return-27.49%
Quick Ratio (Annual)11.08x
13-Week Price Return-6.53%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)11.32x
Enterprise Value$1,087.161
Revenue / Share Growth (5Y)-21.90%
Asset Turnover (TTM)0.06x
Book Value / Share Growth (5Y)0.86%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-236.39%
Cash / Share (Annual)$1.78
3-Month Return Std Dev71.20%
Net Income / Employee (TTM)$-0
ROE (Last FY)-15.14%
Net Interest Coverage (Annual)75.61x
EPS Basic Excl Extra (Annual)$-0.49
P/FCF (TTM)3.51x
Receivables Turnover (TTM)1.63x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.49
Receivables Turnover (Annual)1.63x
ROI (TTM)-14.79%
P/S Ratio (TTM)16.18x
Pretax Margin (5Y Avg)-256.28%
Revenue / Share (Annual)$0.25
Tangible BV / Share (Annual)$3.09
Price vs S&P 500 (52W)32.69%
Year-to-Date Return17.25%
5-Day Price Return9.56%
EPS Normalized (Annual)$-0.49
ROA (5Y Avg)-2.13%
Net Profit Margin (Annual)-194.88%
Month-to-Date Return14.90%
Cash Flow / Share (TTM)$-0.34
EBITD / Share (Annual)$-0.62
Operating Margin (Annual)-288.98%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-3.09%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.49
P/TBV (Quarterly)1.10x
P/B Ratio (Annual)1.06x
Pretax Margin (TTM)-236.39%
Book Value / Share (Annual)$3.22
Price vs S&P 500 (13W)-9.39%
Beta0.99x
P/FCF (Annual)5.94x
Revenue / Share (TTM)$0.25
ROE (TTM)-14.79%
52-Week Low$1.94
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.07
4.07
4.07
4.07
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ABCLAbCellera Biologics Inc. Common Shares | 16.18x | 160.55% | — | — | $3.91 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
AbCellera is an antibody discovery platform that accelerates clinical candidate identification through proprietary hardware, software, and data science. The company partners with biotechnology and pharmaceutical firms to discover optimized antibody therapies faster and more efficiently than conventional discovery methods. AbCellera's integrated platform reduces time to clinic and de-risks development programs for its partners.